Harmony Biosciences holder plans 700K share sale

Harmony Biosciences shareholder VALOR IV PHARMA HOLDINGS LLC filed to sell up to 700,883 shares of common stock, which were acquired on 10/06/2017 through a Private Acquisition from Issuer/Affiliate for cash.

Rhea-AI Filing Summary

Harmony Biosciences shareholder VALOR IV PHARMA HOLDINGS LLC filed to sell up to 700,883 shares of common stock, which were acquired on 10/06/2017 through a Private Acquisition from Issuer/Affiliate for cash. The class of common stock has an aggregate market value of $26,563,465.70 and 58,236,393 shares outstanding as of 08/07/2026 on NASDAQ; this is a baseline figure, not the amount being sold. The filing also lists prior sales over the past three months totaling 116,490 shares for approximately $4,332,549.00.

Key Figures

Shares to be sold: 700,883 shares Aggregate market value of class: $26,563,465.70 Shares outstanding: 58,236,393 shares +4 more

7 metrics

Shares to be sold 700,883 shares Maximum number of Harmony Biosciences common shares planned for sale by VALOR IV PHARMA HOLDINGS LLC

Aggregate market value of class $26,563,465.70 Aggregate market value of the referenced Harmony Biosciences common stock class as of 08/07/2026

Shares outstanding 58,236,393 shares Harmony Biosciences common shares outstanding as of 08/07/2026 for the referenced class

Past sale 1 55,847 shares for $2,104,873.00 Sale of Harmony Biosciences common stock on 08/05/2026 by VALOR IV PHARMA HOLDINGS LLC

Past sale 2 45,642 shares for $1,727,093.00 Additional sale of Harmony Biosciences common stock on 08/05/2026 by the same holder

Past sale 3 15,001 shares for $500,583.00 Sale of Harmony Biosciences common stock on 06/22/2026 by VALOR IV PHARMA HOLDINGS LLC

Total recent sales 116,490 shares for $4,332,549.00 Combined Harmony Biosciences share sales over the past three months by the reporting holder

Key Terms

Private Acquisition from Issuer/Affiliate, aggregate market value, Executive Financial Services

3 terms

Private Acquisition from Issuer/Affiliate financial

"Common | 10/06/2017 | Private Acquisition from Issuer/Affiliate | Issuer"

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC... | 26563465.70"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Harmony Biosciences (HRMY) disclose in this Form 144 filing?

The filing states that VALOR IV PHARMA HOLDINGS LLC plans to sell up to 700,883 shares of Harmony Biosciences common stock, originally acquired in 2017 via a private acquisition from the issuer or an affiliate.

How many Harmony Biosciences (HRMY) shares are being registered for sale?

The shareholder intends to sell up to 700,883 shares of common stock. This amount represents the maximum size of the planned Rule 144 sale listed for VALOR IV PHARMA HOLDINGS LLC in the notice.

What recent sales has VALOR IV PHARMA HOLDINGS LLC made in HRMY stock?

Over the past three months, the holder reported selling 116,490 shares of Harmony Biosciences common stock for a combined value of about $4,332,549.00 on 06/22/2026 and 08/05/2026.

When and how were the HRMY shares to be sold originally acquired?

The 700,883 shares listed for sale were acquired on 10/06/2017 through a Private Acquisition from Issuer/Affiliate, with the consideration described as cash paid to the issuer or affiliate.

What is the aggregate market value of Harmony Biosciences common stock in this class?

The class of Harmony Biosciences common stock referenced has an aggregate market value of $26,563,465.70, with 58,236,393 shares outstanding as of 08/07/2026 on NASDAQ, providing context for the planned sale.

Who is listed as the broker in the Harmony Biosciences (HRMY) Form 144?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, associated with the planned sale of Harmony Biosciences common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:50 PM Accepted by SEC EDGAR 08/07/2026 - 04:48 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001821186
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	HARMONY BIOSCIENCES HOLDINGS, INC.
SEC File Number	001-39450
Address of Issuer	630 W GERMANTOWN PIKE SUITE 215 PLYMOUTH MEETING PENNSYLVANIA 19462
Phone	(484) 539-9800
Name of Person for Whose Account the Securities are To Be Sold	VALOR IV PHARMA HOLDINGS LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	700883	26563465.70	58236393	08/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/06/2017	Private Acquisition from Issuer/Affiliate	Issuer			700883	10/06/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
VALOR IV PHARMA HOLDINGS LLC 630 W. Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	08/05/2026	55847	2104873.00
VALOR IV PHARMA HOLDINGS LLC 630 W. Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	08/05/2026	45642	1727093.00
VALOR IV PHARMA HOLDINGS LLC 630 W. Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	06/22/2026	15001	500583.00

144: Remarks and Signature

Remarks
Date of Notice	08/07/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jonathan Shulkin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)